Abstract:Background The study aimed to explore the relationship between non-alcoholic fatty liver disease (NAFLD) and mortality by age and metabolic syndrome (MetS) components. Method We enrolled 104,173 participants in the Kailuan cohort from June 2006 through October 2013. Cox regression models were used to evaluate the hazard ratio (HR) and 95% confidence interval (CI). Population-attributable fractions (PAFs) of metabolic components were also calculated. Results Compared with non-NAFLD, the excess risk of all-cause and cardiovascular disease (CVD)-related mortality in NAFLD increased with the number of MetS components but decreased with age. The highest all-cause and CVD-related death risks were observed in NAFLD aged 18-39 with 4-5 MetS (HR=2.81, 95% CI:1.55-5.08) and those aged 40-49 years with 3 MetS (HR=2.25, 95% CI:1.55-5.08), respectively. However, there was no significant extra risk of liver-related death in NAFLD patients of any age. For PAF, 28.5% of all-cause and 43.4% of CVD-related mortality among NAFLD patients was preventable by controlling MetS components < 2, with the highest PAF in those aged 50-69 and 18-49, respectively. Elevated blood pressure (PAF of 24.7% for all-cause; 38.6% for CVD-related), elevated fasting glucose (PAF of 13.4% all-cause; 9.2% CVD-related), and elevated triglycerides (PAF of 3.9% all-cause; 14.0% CVD-related) were the essential mortality contributors in NAFLD participants. Conclusion The excess risk of all-cause and CVD-related mortality in NAFLD patients decreases with age. A substantial proportion of risks could be averted if NAFLD patients are controlled under two MetS components, especially managing blood pressure, fasting glucose, and triglycerides for the young. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement Yes, We have included details of all funding supported in the work presented ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Ethics Committees of the Kailuan General Hospital and the Institute of Basic Medical Sciences Chinese Academy of Medical Sciences approved this study. We obtained informed consent from all participants. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes

Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study

Hepatic Fibrosis and Steatosis in Metabolic Syndrome

Metabolic perturbations prior to hepatocellular carcinoma diagnosis: Findings from a prospective observational cohort study

Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults

Clinical outcomes of metabolic liver disease versus non-alcoholic fatty liver disease: a meta-analysis of observational studies

Fatty liver index as an independent predictor of all-cause and disease-specific mortality

Linear age-course association between non-alcoholic fatty liver disease, components of metabolic syndrome, and mortality

Extrahepatic Morbidities and Mortality of NAFLD: an Umbrella Review of Meta-Analyses

Prevalence, proportions of elevated liver enzyme levels, and long‐term cardiometabolic mortality of patients with metabolic dysfunction‐associated steatotic liver disease

Association of metabolic syndrome components and NAFLD with quality of life: Insights from a cross-sectional study

The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity

Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study

Long‐term prognosis of patients with alcohol‐related liver disease or non‐alcoholic fatty liver disease according to metabolic syndrome or alcohol use

Impact of non‐alcoholic fatty liver disease and fibrosis on mortality and kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A multi‐cohort longitudinal study

Long‐term all‐cause mortality of metabolic‐dysfunction associated steatotic liver disease based on body weight phenotypes following acute myocardial infarction: A retrospective cohort study

Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States

Cardiometabolic Phenotype Linked to Fibrosis and Mortality in Metabolic Dysfunction-Associated Steatotic Liver Disease

Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies

Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality

Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort

Multipanel Approach including miRNAs, Inflammatory Markers, and Depressive Symptoms for Metabolic Dysfunction-Associated Steatotic Liver Disease Diagnosis during 2-Year Nutritional Intervention